Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in advanced EGFR-expressing chordoma
NL-OMON54671Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in chordoma, sponsored by Leiden University Medical Center. Primary endpoints: Progression-free survival threshold and Quality of life and pain. Started Jun 2018; status: completed.
02
Drugs
afatinib
03
Conditions
chordoma
Beyond the preview
Go deeper on NL-OMON54671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54671.